GeneDx Holdings

GeneDx Holdings CROIC

The Cash Return on Invested Capital (CROIC) of GeneDx Holdings (WGS) as of Oct 25, 2026 is 3.90 %. In the previous year, Cash Return on Invested Capital (CROIC) was -10.71 % — a change of -136.45% (higher).

CROIC

3.90 %

YoY

-136.45%

Last updated:

Cash Return on Invested Capital (CROIC) of GeneDx Holdings is 2025 3.90 % . Cash Return on Invested Capital (CROIC) of GeneDx Holdings was 2024 -10.71 % . It decreases by -136.45% higher compared to the previous year.

The GeneDx Holdings CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
-136.74 USD
Jan 1, 2020
-253.30 USD
Jan 1, 2021
-50.18 USD
Jan 1, 2022
-119.44 USD
Jan 1, 2023
-61.74 USD
Jan 1, 2024
-10.71 USD
Jan 1, 2025
3.90 USD
The GeneDx Holdings CROIC history
YEARCROICYoY
3.90 %-136.45%
-10.71 %-82.65%
-61.74 %-48.31%
-119.44 %+138.01%
-50.18 %-80.19%
-253.30 %+85.25%
-136.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneDx Holdings Stock analysis

What does GeneDx Holdings do? GeneDx Holdings Corp. generates revenue through its GeneDx and Legacy Sema4 segments. The GeneDx segment offers pediatric and rare disease diagnostics, primarily utilizing whole exome and genome sequencing, along with data and information services. It provides genetic diagnostic tests, screening solutions, and information to clinicians and patients. The Legacy Sema4 segment delivers reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. Both segments target healthcare providers and institutions seeking personalized health insights for diagnosis, treatment planning, and drug discovery. The company’s products include genetic diagnostic tests, screening solutions, and information services under the GeneDx brand, while Legacy Sema4 focuses on reproductive health, women’s health, and oncology diagnostics. These services are sold to healthcare providers and institutions that require actionable health intelligence to inform clinical decisions and improve patient outcomes. The segments serve distinct medical specialties, with GeneDx emphasizing rare diseases and pediatric care, and Legacy Sema4 covering reproductive health and cancer diagnostics. Revenue is derived from diagnostic testing services provided through both segments. The GeneDx segment’s core offerings are whole exome and genome sequencing for rare and pediatric conditions, while Legacy Sema4 specializes in reproductive, women’s health, and somatic oncology testing. These services are delivered to healthcare systems and providers who integrate genetic data into patient care pathways for better diagnosis and treatment strategies. GeneDx Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneDx Holdings stock

Cash Return on Invested Capital (CROIC) of GeneDx Holdings is 3.90 % in 2025.

Cash Return on Invested Capital (CROIC) of GeneDx Holdings changed from -10.71 % to 3.90 %, representing a -136.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) GeneDx Holdings since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s GeneDx Holdings with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GeneDx Holdings

All Key Metrics — GeneDx Holdings